$TPST

Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules

$4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of short-term unregistered warrants $4.25 million upfront with up to an additional $4.1 million of potential aggregate gross proceeds upon the exercise in full of ...

Original reporting
GlobeNewswire · Tempest Therapeutics
Published Nov 26, 2025, 9:05 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 26, 2025, 10:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Tempest Announces Closing of Up To $8.35 Million Registered Direct Offering of Common Stock and Concurrent Private Placement of Warrants Priced At-the-Market Under Nasdaq Rules — source image
Decision brief

The 30-second read

$TPSTNeutralLow
01

Why it matters

The funding round provides financial stability, possibly enabling accelerated development timelines and strategic partnerships.

02

Market read

The news is relevant to biotech investors and may influence Tempest's stock in the short term, with limited broader market impact.

03

What to watch

Market conditions and investor appetite for biotech funding rounds may influence the stock's reaction beyond the company's fundamentals.

Timing: short-term (within days to weeks)

Background

Tempest Therapeutics is engaged in developing targeted cancer therapies. The recent financing supports ongoing R&D efforts.

Company-level read

Ticker impact

$TPSTNeutralMedium confidence
Context

The news involves Tempest Therapeutics' financing activities, which may influence its stock price.

Expected impact

Limited immediate impact; potential for short-term volatility due to dilution concerns.

Evidence & confidence

The announcement of capital raising is a common corporate activity with mixed short-term effects. The neutral sentiment reflects the lack of immediate positive or negative signals, but the potential for future positive developments exists.

Market effects

Potential positive impact on biotech and life sciences sectors due to increased funding for innovative therapies.

Limited regional impact; primarily affects US-based biotech sector.

Minimal direct global market impact; relevant mainly to biotech investors.

Counterpoint

The capital raise could lead to dilution, potentially pressuring stock prices in the short term.

Key entities

  • Tempest Therapeutics

    A biotech company focused on oncology therapeutics.

Related articles

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.